Product
BITR2101
1 clinical trial
3 indications
Indication
Non-Hodgkin lymphomaIndication
Cutaneous T-Cell LymphomaIndication
Peripheral T-cell LymphomaClinical trial
A Phase 1, First-In-Human, Open-Label, Dose-Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Intravenous Doses of BITR2101 (Anti-TNFR2) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Including Cutaneous and Peripheral T Cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2027-02-01